Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Operating Income of -$403.36 million for fiscal year 2025.
IOVANCE BIOTHERAPEUTICS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$403.36M | -2.0% |
| 2024 | -$395.28M | +14.2% |
| 2023 | -$460.56M | -15.5% |
| 2022 | -$398.88M | -16.4% |
| 2021 | -$342.70M | -30.8% |
| 2020 | -$261.94M | -26.6% |
| 2019 | -$206.87M | -61.3% |
| 2018 | -$128.26M | -38.1% |
| 2017 | -$92.88M | -73.2% |
| 2016 | -$53.64M | -92.5% |
| 2015 | -$27.86M | -131.4% |
| 2014 | -$12.04M | +46.8% |
| 2013 | -$22.64M | -178.4% |
| 2012 | -$8.13M | +61.7% |
| 2011 | -$21.22M | -2502.2% |
| 2010 | -$815.4K | -5070.0% |
| 2009 | -$15.8K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$94.90M | -6.6% | +16.6% |
| June 30, 2025 | -$113.77M | -11.6% | +6.1% |
| March 31, 2025 | -$121.22M | -3.0% | -36.1% |
| September 30, 2024 | -$89.07M | +24.8% | +12.6% |
| June 30, 2024 | -$101.91M | +7.4% | +13.4% |
| March 31, 2024 | -$117.72M | -6.2% | +0.5% |
| September 30, 2023 | -$118.36M | -17.9% | -7.5% |
| June 30, 2023 | -$110.09M | -10.4% | +0.7% |
- IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -2.0% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, IOVANCE BIOTHERAPEUTICS, INC.’s operating income has declined by 2557318.2% (from -$15.8 thousand to -$403.36 million).
- The most recent figure is from IOVANCE BIOTHERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: